Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 6Lung Neoplasms 5Thymus Neoplasms 1Thymoma 1Sarcoma 1Multiple Myeloma 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

Sunitinib 3Thymectomy 2Taxes 2Prednisone 2Pemetrexed 2Paclitaxel 2Octreotide 2Imatinib Mesylate 2Erlotinib Hydrochloride 2Cisplatin 2Carboplatin 2vorolanib 1regorafenib 1pembrolizumab 1olaparib 1lenvatinib 1entinostat 1bosutinib 1belinostat 1atezolizumab 1anetumab ravtansine 1amrubicin 1Ramucirumab 1Radiotherapy 1Radiosurgery 1Radiofrequency Ablation 1Psychiatric Rehabilitation 1Prednisolone 1Patient Comfort 1Palliative Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thymoma × amrubicin × Clear all
NCT01364727 2019-04-16

A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies

Stanford University

Phase 2 Completed
33 enrolled 11 charts
Thoracic

Thymoma, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡